595,962 Shares in Grail, Inc. (NASDAQ:GRAL) Bought by Bank of America Corp DE

Bank of America Corp DE acquired a new position in Grail, Inc. (NASDAQ:GRAL - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 595,962 shares of the company's stock, valued at approximately $10,638,000. Bank of America Corp DE owned 1.77% of Grail as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of GRAL. Crcm LP acquired a new position in shares of Grail during the fourth quarter valued at approximately $65,061,000. Primecap Management Co. CA bought a new position in Grail during the fourth quarter valued at about $37,118,000. Vanguard Group Inc. acquired a new position in Grail during the fourth quarter worth about $25,902,000. AQR Capital Management LLC bought a new stake in Grail in the fourth quarter worth about $14,828,000. Finally, Arbiter Partners Capital Management LLC acquired a new stake in Grail in the 4th quarter valued at about $14,827,000.

Grail Stock Performance

Shares of NASDAQ:GRAL traded up $2.16 during mid-day trading on Tuesday, hitting $42.34. The stock had a trading volume of 1,533,368 shares, compared to its average volume of 1,257,181. Grail, Inc. has a 12-month low of $12.33 and a 12-month high of $63.99. The company has a market cap of $1.52 billion and a PE ratio of -0.69. The company's 50 day moving average is $31.24 and its 200-day moving average is $27.79.

Grail (NASDAQ:GRAL - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($3.10) earnings per share for the quarter, beating the consensus estimate of ($4.03) by $0.93. The business had revenue of $31.84 million for the quarter, compared to analysts' expectations of $35.80 million. On average, equities research analysts predict that Grail, Inc. will post -15.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GRAL has been the subject of several recent research reports. Canaccord Genuity Group increased their target price on shares of Grail from $32.00 to $43.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. Morgan Stanley upped their price target on Grail from $16.00 to $20.00 and gave the company an "equal weight" rating in a report on Tuesday, March 18th.

Insider Buying and Selling at Grail

In related news, President Joshua J. Ofman sold 2,109 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $31.20, for a total value of $65,800.80. Following the completion of the sale, the president now owns 559,673 shares of the company's stock, valued at approximately $17,461,797.60. The trade was a 0.38% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Robert P. Ragusa sold 7,625 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $31.21, for a total value of $237,976.25. Following the completion of the transaction, the chief executive officer now owns 828,662 shares in the company, valued at $25,862,541.02. This represents a 0.91% decrease in their position. The disclosure for this sale can be found here. Insiders sold 194,948 shares of company stock valued at $6,583,130 in the last quarter. Company insiders own 1.85% of the company's stock.

Grail Company Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.